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THE original observations that the placenta produces a gonadotrophic hormone
which is excreted in the urine (Hirose, 1920; Aschheim and Zondek, 1927) were
soon followed by identification of a similar hormone in the urine and blood of
patients with hydatidiform mole and choriocarcinoma (Zondek, 1929, 1942;
Hamburger, 1944). These conditions were sometimes found to be associated with
higher excretion rates of human chorionic gonadotrophin (HCG) than were
usually found in normal pregnancy but it is now recognised that in choriocarcinoma
high values simply reflect extensive disease and in many instances the excretion
rates of HCG are comparable to, or lower than those of normal pregnancy.
The problem of distinguishing hydatidiform mole and choriocarcinoma from
normal pregnancy led Ehrhardt (1931) to examine the spinal fluid for gonado-
trophic activity by the Aschheim-Zondek test. He obtained positive responses
with CSF from 2 patients with hydatidiform mole but no response with the CSF of
normal pregnant women. Zondek (1937, 1942), Mathieu (1939) and Vesell and
Goldman (1941) confirmed these findings on small groups of patients with inole,
choriocarcinoma and normal pregnancy. On their evidence a positive pregnancy
test on spinal fluid acquired a reputation as a means for distinguishing chorio-
carcinoma from normal pregnancy. McCormick (1954) studied patients with
hydatidiform mole and also infused HCG into a nephrectomised dog. He
concluded that the ratio ofblood and spinal fluid concentrations was about 187: 1
and that HCG did not appear in the CSF until a high threshold value (excretion
of 250,000 i.u. HCG/day in the urine) was exceeded. Tashima et al., (1965) also
concluded that HCG did not appear in the CSF until a high threshold value was
exceeded unless the patient had brain metastases from choriocarcinoma.
Radioimmunoassay provides a more sensitive method for the quantitation
of gonadotrophic hormones than the bioassay methods previously used. By
radioimmunoassay it has been found that the concentration of HCG in the CSF
ofpatients with trophoblastic tumours is directly proportional to the concentration
in the plasma (Bagshawe, Orr, and Rushworth, 1968). In the present paper we
compare the concentration of HCG in the CSF of patients with choriocarcinoma
which has metastasised to the central nervous system (CNS) with the values found
in patients who had no evidence of such metastases.
MATERIALS AND METHODS
Details of the method, sensitivity and specificity of the radioimmunoassay
have been described by Wilde, Orr and Bagshawe (1965, 1967) and by Bagshawe,
Wilde and Orr (1966). The method estimates both HCG and luteinising hormone
(LH) and requires approximately 1 ml. of the sample fluid. Total CSF protein
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Samples.-CSF was obtained by lumbar puncture without preservative or
anticoagulant and was stored at - 15° C. till assayed. Plasma samples were
collected at the time of lumbar puncture with 2 mg./ml. EDTA as anticoagulant.
Subjects.-Spinal fluid was obtained from 17 females with post-gestational
trophoblastic tumours and from 2 males with choriocarcinoma which probably
originated inthetestis.
Spinal fluid was also obtained from 10 hospitalised non-pregnant subjects
who did not have trophoblastic disease but who underwent lumbar puncture in
the course of clinical investigations. Histological evidence of choriocarcinoma
was obtained for 10 of the female and for both male patients. Seven female
patients were classified as invasive trophoblastic neoplasia (choriocarcinoma or
invasive mole) since histological evidence was deficient. There was clinical
evidence of intracranial or spinal metastases in 7 instances and autopsy confir-
mation was obtained in 3 ofthese.
RESULTS
The total CSFprotein concentrations in the patients studied were eithernormal
or only slightly elevated. Gonadotrophic activity was not found in the CSF
ofsubjects with normal plasma concentrations ofluteinising hormone.
The results obtained on patients with elevated plasma gonadotrophins values
are shown in Table I.
TABLE I.-Plasma and CSF HCG Concentrations in Patients with
Trophoblastic Tumours
HCG i.u./ml.
A & A Plasma/
Case No. Plasma CSF CSF ratio Brain metastases
49 . 0056 0.140 . 004 . +
69 . 0320 0-003 . 106 . -
85 . 0890 1 77 . 051 . +
86 . 400 2.00 . 20 . +
87 . 51-5 1.62 . 322 +
111 . 0 280 0-002 140 . -
129 . 0117 0 004 . 293 . +
132 . 280 3-55 790 -
133 . 152 0 009 . 169 . -
136 . 2890 550 . 526 . +
149 17 6 0-088 . 200 -
153 18 0 0-094 . 192 . -
157 12.0 0-127 . 945 -
161 . 2.17 0 007 . 311 -
163 22-1 0-930 . 237 . +
164 1-88 0-009 . 209 . -
169 . 0-700 0 006 . 117 . -
191 . 270 0-450 600 . -
193 . 362 0-015 . 240 . -
One pair of estimates of corresponding plasma and CSF concentrations is
given for each patient: these were the first estimates for each subject, except in
one instance where the estimates given were the first to be obtained after other
criteria had confirmed the presence ofbrain metastases. The HCG concentrations
in plasma and CSF are plotted on a double logarithmic scale in Fig. 1 for the 2
groups, those with ( *) and those without (A) brain metastases.
For each of the 2 sets of points, the log HCG CSF and log HC1G plasma areHCG IN THE PLASMA AND SPINAL FLUID
significantly correlated (group with brain metastases P < 002, group without
brain metastases P < 0001-two-sided tests) and the data are adequately
represented by the simple relationships: CSF HCG i.u./ml. -= a x Plasma
HCG i.u./ml. where a -0O21 for the group with brain metastases (solid line in
Fig. 1) and a = 0*0057 for the group without brain metastases (dotted line in
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Fig. 1). The value for one subject (B.A.) contributed greatly to the significant
level of 002 quoted for the brain metastases group but his exclusion did not
materially alter the value of " a " in the equation ofbest fit.
DISCUSSION
The results indicate a close relation between the concentrations of HCG in the
plasma and CSF of patients with choriocarcinoma over a wide range of values.
Our findings are therefore contrary to those of Zondek (1937), McCormick (1954)
and Tashima et al., (1965) who reported that HCG was found in the CSF only when
the urinary excretion rate was high and the blood brain barrier overwhelmed by
very high titres.
It is suggested that the concept of a threshold effect probably arose from the
limitation of the bioassay methods used by earlier workers. Their methods were
unsuitable for estimations on plasma and they therefore compared urine excretion
rates with CSF concentrations. The renal clearance ofHCG is 1-0-1 5 ml./min. so
that urine and plasma concentrations tend to be similar. The threshold value
reported by these workers was about 200,00 i.u. HCG/day which would correspond
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to a plasma concentration of about 150-200 i.u. HCG/ml. Since our estimate of
the mean plasma : CSF ratio is 177 : 1 the concentration ofHCG in the CSF at the
" threshold value " would be about 1 i.u. HCG/ml. Although these authors did
not give precise estimates of the sensitivity of their methods, it is unlikely that
their methods could detect concentrations much lower than 1 i.u. HCG/ml. and
their conclusion that HCG was absent from the CSF at lowerurinary excretion rates
may be attributed to the inability oftheir methods to detect it.
The radioimmunoassay used in the present study, in common with other
biological and immunological methods, does not estimate HCG and LH indepen-
dently when both are present. The presence ofHCGis inferred when the estimates
obtained exceed the LH values which are normal for a subject's age, sex and
endocrine status. The contribution from LH does not usually exceed the equiva-
lent of 0-2 i.u. HCG/ml. plasma whereas all but 2 of the subjects studied here had
higher values. Since all the subjects were known to have trophoblastic tumours
which synthesise HCG and since LH was not detected in the CSF of normal,
pre-menopausal, non-pregnant subjects by the radioimmunoassay technique, the
results have been interpreted only in terms of HCG.
Patients who had intracranial or spinal metastases from choriocarcinoma had
higher concentrations of HCG in the CSF relative to the plasma than those who
did not, and they were especially high in those patients whose active tumour was
located mainly in the brain or spinal cord. Plasma: CSF values which were
characteristic of intracranial disease proved to have diagnostic value. For
instance, in one patient they gave evidence of an intracranial metastasis some
weeks before other objective abnormalities were present. Another patient had
evidence of left cerebro-cortical and right orbital metastases at the time of ad-
mission and after 6 months' chemotherapy his gonadotrophin excretion had
fallen to the normal range. Some weeks after gonadotrophin excretion rates had
been persistently in the normal range, but whilst still being treated, it was found
that he had a relatively high CSF concentration of HCG. This suggested that
viable tumour cells remained in the CNS and following therapy directed at the
intracranial tumour, his mean gonadotrophin excretion rate has shown a further
fall. Evidence of intracranial growth influences the duration, route and type of
therapy so that determination ofthe CSF HCG concentration is ofpractical value.
When plasma and CSF concentrations of HCG have been determined their
significance can be assessed either by application of the regression line formulae
given in the results section or by plotting them on a double logarithmic scale such
as is shown in Fig. 1. The ratios of plasma: CSF were above 100 1 in most of
the patients who did not have intracranial disease and below 35 1 in patients
who did. It is likely that the amounts ofhormone in the plasma and CSF respec-
tively are determined by the anatomical distribution of metastases and their
respective endocrine activity so that a wide spread of values is to be expected
for patients who have tumours both within and without the CNS. The present
evidence is too limited to exclude the possibility that a metastasis may be so
located within the CNS that significant amounts of hormone do not reach the
CSFdirectly and a normal plasma: CSF ratio should not be regarded as conclusive
evidence ofthe absence ofsuch a lesion.
It is also important to emphasise that rapid changes in the plasma concentra-
tion of HCG are not promptly reflected in the CSF and its relatively low con-
centration in the CSF in the absence of intracranial metastases, is typical of
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proteins in general. In comparison with serum, the CSF contains a relatively
high proportion of fl-globulin and a low proportion ofy-globulin (Davson, 1967)
but although HCG is a fl-globulin its relative concentrations in the CSF do not
appear to be higher than those of proteins in general.
It would therefore be expected that primary changes in the plasma or CSF
concentrations would not be promptly reflected in the other compartment. Our
preliminary observations on this aspect of the problem suggest that equilibrium
may take a week or more to achieve following a rapid thousand-fold change in the
plasma concentration. Thus, a CSF sample, obtained soon after a rapid and
profound fall in the plasma HCG concentration shows a relatively high concentra-
tionofHCGanddoesnotthenindicate thepresence ofCNS metastases. Similarly,
a rapidly rising plasma concentration of HCG could temporarily obscure the
evidence ofan active lesion in the central nervous system. It is therefore essential
to take account of recent fluctuations in the plasma concentration and in many
instances serial determinations will be necessary.
The detection ofintracranial metastases by endocrine studies on the CSF may
be applicable to other hormone producing tumours. The observations reported
here draw attention to the suitability of radioimmunoassay techniques for the
study of specific proteins in CSF.
SUMMARY
The concentration of chorionic gonadotrophin in the spinal fluid of patients
with trophoblastic tumours is directly proportional to its concentration in the
plasma. The factor of proportionality is higher in patients with intracranial
metastases than in patients without metastases and this fact may provide early
evidence ofmetastases in the brain or spinal cord. The interpretation ofplasma:
CSF concentrations of the hormone requires recent fluctuations of the plasma
concentration to be taken into account.
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